BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27353170)

  • 1. A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells.
    Schmittnaegel M; Hoffmann E; Imhof-Jung S; Fischer C; Drabner G; Georges G; Klein C; Knoetgen H
    Mol Cancer Ther; 2016 Sep; 15(9):2130-42. PubMed ID: 27353170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Committing Cytomegalovirus-Specific CD8 T Cells to Eliminate Tumor Cells by Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules.
    Schmittnaegel M; Levitsky V; Hoffmann E; Georges G; Mundigl O; Klein C; Knoetgen H
    Cancer Immunol Res; 2015 Jul; 3(7):764-76. PubMed ID: 25691327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo.
    Fischer C; Munks MW; Hill AB; Kroczek RA; Bissinger S; Brand V; Schmittnaegel M; Imhof-Jung S; Hoffmann E; Herting F; Klein C; Knoetgen H
    MAbs; 2020; 12(1):1834818. PubMed ID: 33151105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells.
    Massafra V; Tundo S; Dietzig A; Ducret A; Jost C; Klein C; Kontermann RE; Knoetgen H; Steegmaier M; Romagnani A; Nagel YA
    J Immunol; 2021 Jul; 207(2):493-504. PubMed ID: 34215653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep.
    Rojas JM; Rodríguez-Calvo T; Peña L; Sevilla N
    Vaccine; 2011 Sep; 29(40):6848-57. PubMed ID: 21807057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A soluble divalent class I MHC/IgG1 fusion protein activates CD8+ T cells in vivo.
    Carey B; DeLay M; Strasser JE; Chalk C; Dudley-McClain K; Milligan GN; Brunner HI; Thornton S; Hirsch R
    Clin Immunol; 2005 Jul; 116(1):65-76. PubMed ID: 15925833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD8 antibodies can inhibit or enhance peptide-MHC class I (pMHCI) multimer binding: this is paralleled by their effects on CTL activation and occurs in the absence of an interaction between pMHCI and CD8 on the cell surface.
    Wooldridge L; Hutchinson SL; Choi EM; Lissina A; Jones E; Mirza F; Dunbar PR; Price DA; Cerundolo V; Sewell AK
    J Immunol; 2003 Dec; 171(12):6650-60. PubMed ID: 14662868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
    Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
    Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An active CD8alpha/pMHCI interaction is required for CD8 single positive thymocyte differentiation.
    Kang YJ; Wang X; Lin SJ; Hsu YM; Chang HC
    Eur J Immunol; 2010 Mar; 40(3):836-48. PubMed ID: 19950178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional heterogeneity of cytokines and cytolytic effector molecules in human CD8+ T lymphocytes.
    Sandberg JK; Fast NM; Nixon DF
    J Immunol; 2001 Jul; 167(1):181-7. PubMed ID: 11418647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic epitopes fused to cationic peptide bound to oligonucleotides facilitate Toll-like receptor 9-dependent, but CD4+ T cell help-independent, priming of CD8+ T cells.
    Schirmbeck R; Riedl P; Zurbriggen R; Akira S; Reimann J
    J Immunol; 2003 Nov; 171(10):5198-207. PubMed ID: 14607920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting the efficiency of CD8+ T cell cross-priming with exogenous antigens.
    Maecker HT; Ghanekar SA; Suni MA; He XS; Picker LJ; Maino VC
    J Immunol; 2001 Jun; 166(12):7268-75. PubMed ID: 11390476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes.
    Simon P; Omokoko TA; Breitkreuz A; Hebich L; Kreiter S; Attig S; Konur A; Britten CM; Paret C; Dhaene K; Türeci Ö; Sahin U
    Cancer Immunol Res; 2014 Dec; 2(12):1230-44. PubMed ID: 25245536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric beta2 microglobulin/CD3zeta polypeptides expressed in T cells convert MHC class I peptide ligands into T cell activation receptors: a potential tool for specific targeting of pathogenic CD8(+) T cells.
    Margalit A; Fishman S; Berko D; Engberg J; Gross G
    Int Immunol; 2003 Nov; 15(11):1379-87. PubMed ID: 14565936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
    Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
    J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T Cells Engaging the Conserved MHC Class Ib Molecule Qa-1
    Doorduijn EM; Sluijter M; Querido BJ; Seidel UJE; Oliveira CC; van der Burg SH; van Hall T
    Front Immunol; 2018; 9():60. PubMed ID: 29422902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-Transgenic mice and for ex vivo stimulation and expansion of CD8(+) cytotoxic T cells from human peripheral blood cells.
    Rohrlich PS; Cardinaud S; Lulè J; Montero-Julian FA; Prodhomme V; Firat H; Davignon JL; Perret E; Monseaux S; Necker A; Michelson S; Lemonnier FA; Charneau P; Davrinche C
    Hum Immunol; 2004 May; 65(5):514-22. PubMed ID: 15172452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presentation and binding affinity of equine infectious anemia virus CTL envelope and matrix protein epitopes by an expressed equine classical MHC class I molecule.
    McGuire TC; Leib SR; Mealey RH; Fraser DG; Prieur DJ
    J Immunol; 2003 Aug; 171(4):1984-93. PubMed ID: 12902502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer.
    Hernandez-Hoyos G; Sewell T; Bader R; Bannink J; Chenault RA; Daugherty M; Dasovich M; Fang H; Gottschalk R; Kumer J; Miller RE; Ravikumar P; Wiens J; Algate PA; Bienvenue D; McMahan CJ; Natarajan SK; Gross JA; Blankenship JW
    Mol Cancer Ther; 2016 Sep; 15(9):2155-65. PubMed ID: 27406985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.